Mabsolve
Our founders were pioneers of monoclonal antibody therapy, bringing to the clinic the first humanised antibody, the first made in CHO cells, the first bispecific and the first aglycosylated antibody. Now we have developed a new Fc variant which is more comprehensively silenced than previous antibodies. It is able to reduce unwanted inflammatory responses from the next generation of antibody-based drugs. We are building partnerships with Universities, Biotech and Pharma companies to make this new technology widely available.
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
6
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 2 verified contacts at Mabsolve
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Mabsolve
2 distinct titles indexed · top 2 shown.
- 1chief executive officer
- 1founder investor and scientific advisor
Sign up to unlock all 2 contacts at Mabsolve
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Mabsolve
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.